KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Inovio Pharmaceuticals (INO) over the last 17 years, with Q1 2025 value amounting to 38336.97%.

  • Inovio Pharmaceuticals' EBITDA Margin changed N/A to 38336.97% in Q1 2025 from the same period last year, while for Sep 2025 it was 49202.88%, marking a year-over-year increase of 95067900.0%. This contributed to the annual value of 51616.91% for FY2024, which is 343166400.0% down from last year.
  • As of Q1 2025, Inovio Pharmaceuticals' EBITDA Margin stood at 38336.97%.
  • In the past 5 years, Inovio Pharmaceuticals' EBITDA Margin registered a high of 390.61% during Q3 2022, and its lowest value of 44876.83% during Q4 2022.
  • For the 5-year period, Inovio Pharmaceuticals' EBITDA Margin averaged around 23434.95%, with its median value being 20553.16% (2021).
  • The largest annual percentage gain for Inovio Pharmaceuticals' EBITDA Margin in the last 5 years was 201625500bps (2022), contrasted with its biggest fall of -323030700bps (2022).
  • Quarter analysis of 5 years shows Inovio Pharmaceuticals' EBITDA Margin stood at 12573.76% in 2021, then tumbled by -257bps to 44876.83% in 2022, then surged by 41bps to 26686.29% in 2023, then soared by 35bps to 17410.77% in 2024, then tumbled by -120bps to 38336.97% in 2025.
  • Its EBITDA Margin stands at 38336.97% for Q1 2025, versus 17410.77% for Q4 2024 and 32945.87% for Q2 2024.